Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2019-02-11 Capital/Financing Update
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Appendix 3B - issue of shares and unlisted share options 13 pages 158.4KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class and number of securities issued, terms, issue price, purpose, shareholder approvals, and quotation application to the ASX (Australian Securities Exchange). It references specific ASX listing rules (e.g., Rule 7.1, 7.1A) and includes a calculation of placement capacity under these rules. The content is regulatory in nature, focused on the announcement and details of a new share issue and application for quotation of additional securities. It does not contain financial statements, audit opinions, management discussions, or earnings data. It is not a full annual or interim report, nor a call transcript or legal proceeding. The document is a formal announcement of a capital raising event and related securities issuance, fitting the definition of a Capital/Financing Update (CAP).
2019-02-11 English
CEO Update to General Meeting 9 pages 6.3MB
Regulatory Filings
2019-01-29 English
General Meeting - Results of Meeting 3 pages 135.1KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement dated 30 January 2019 providing detailed results of a General Meeting of Invion Limited. It includes voting statistics for each resolution, references to the Corporations Act section 251AA(2), and mentions that all resolutions were passed by poll. The content focuses exclusively on the official results of shareholder votes at a general meeting, with no financial statements or management discussion. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is about 5940 characters, which is sufficient to contain detailed voting results rather than a brief announcement. Therefore, the correct classification is DVA with high confidence.
2019-01-29 English
Appendix 4C - December quarter 6 pages 124.6KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'APPENDIX 4C' for the quarter ending 31 December 2018. Appendix 4C is a standard quarterly cash flow report required by the ASX Listing Rules (specifically Listing Rule 4.7B). The document contains detailed quarterly cash flow statements, including operating, investing, and financing activities, cash balances, payments to directors, and estimated cash outflows for the next quarter. It is a quarterly report with substantive financial data and analysis for a period shorter than a full fiscal year. The document is over 10,000 characters, indicating it is the full report, not just an announcement of a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2018
2019-01-28 English
Invion selects Guilin Xingda for light-therapy manufacture 2 pages 86.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Invion Limited about selecting Guilin Xingda to manufacture light-therapy medical equipment. It details a supply deal and product development related to photodynamic cancer therapies. There is no financial data, no mention of a report being attached or published, no regulatory certifications, no voting results, no management changes, no earnings or interim report data, and no merger or acquisition activity. The content is a corporate update on a manufacturing agreement and product development, which fits best under Capital/Financing Update (CAP) as it relates to a supply deal and strategic partnership impacting the company's capital assets and operations.
2019-01-28 English
Invion appoints cancer experts to Scientific Advisory Board 2 pages 89.5KB
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of new members to the Scientific Advisory Board of Invion Limited. It focuses on management and board changes, specifically the strengthening of the Scientific Advisory Board with experts in cancer therapy. There is no financial data, no regulatory filing references, no voting results, no report publication, and no mention of financial performance or capital changes. The content fits best under Board/Management Information (MANG) as it announces changes in the company's advisory board members.
2019-01-15 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.